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Abstract
Background: The biological properties of thiosemicarbazone have been widely reported. The incorporation of some
transition metals such as Fe, Ni and Cu to thiosemicarbazone complexes is known to enhance its biological effects. In this
study, we incorporated nickel(II) ions into thiosemicarbazone with N4-substitution groups H3L (H; H3L
1, CH3; H3L
2, C6H5;
H3L
3 and C2H5; H3L
4) and examined its potential anti-inflammatory activity.
Methodology/Principal Findings: Four ligands (1–4) and their respective nickel-containing complexes (5–8) were
synthesized and characterized. The compounds synthesized were tested for their effects on NF-kB nuclear translocation,
pro-inflammatory cytokines secretion and NF-kB transactivation activity. The active compound was further evaluated on its
ability to suppress carrageenan-induced acute inflammation in vivo. A potential binding target of the active compound was
also predicted by molecular docking analysis.
Conclusions/Significance: Among all synthesized compounds tested, we found that complex [Ni(H2L
1)(PPh3)]Cl (5)
(complex 5), potently inhibited IkBa degradation and NF-kB p65 nuclear translocation in LPS-stimulated RAW264.7 cells as
well as TNFa-stimulated HeLa S3 cells. In addition, complex 5 significantly down-regulated LPS- or TNFa-induced
transcription of NF-kB target genes, including genes that encode the pro-inflammatory cytokines TNFa, IFNb and IL6.
Luciferase reporter assays confirmed that complex 5 inhibited the transactivation activity of NF-kB. Furthermore, the anti-
inflammatory effect of complex 5 was also supported by its suppressive effect on carrageenan-induced paw edema
formation in wild type C57BL/6 mice. Interestingly, molecular docking study showed that complex 5 potentially interact
with the active site of IKKb. Taken together, we suggest complex 5 as a novel NF-kB inhibitor with potent anti-inflammatory
effects.
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Introduction
Nickel (Ni) is an essential trace element for bacteria, plants,
animals and humans. The concentration of nickel in human tissue
is relatively low (1 mg/L) compared to zinc, iron and copper
(100 mg/L) [1]. Studies to investigate the biological functions of
nickel have expanded dramatically following the discovery of
nickel as an active site metal in the jack bean urease by Zerner and
his co-workers in 1975. We now know that a number of enzymes
depend on nickel, including urease, NiFe hydrogenase, CO
dehydrogenase, acetyl-CoA synthase, methyl-Coenzyme M re-
ductase, glyoxalase I, acireductone dioxygenase, and nickel
containing superoxide dismutase [2]. These nickel-containing
enzymes are utilized in a diverse range of biological reactions
attributed to nickel’s flexibility including varied coordination
numbers, geometries and oxidation states.
Thiosemicarbazone complexes were discovered a few decades
ago and they are now attracting growing interest because of their
pharmacological properties including antiviral, antibacterial,
antimalarial [3,4] and anticancer effects [5]. Thiosemicarbazone
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compounds are the products of condensation reactions of a
suitable aldehyde or ketone with thiosemicarbazide or substituted
thiosemicarbazide at the N4 position. The biological activities of
thiosemicarbazone can be modified or enhanced by the linkage to
important metal ions such as Fe, Ni, Cu and Zn [6]. For example,
nickel complexes of thiosemicarbazone have been shown to
possess anti-proliferative activity in a few cancer cell lines [3,7,8].
Inflammation is a physiological response to injury and infectious
agents, such as viruses and microbes [9]. Studies revealed the
involvement of inflammation in the progression of various diseases,
especially cancers, which supports the hypothesis by Rudolf
Virchow that malignant cancerous cells can originate from sites of
chronic inflammation [9–11]. Transcription factor NF-kB (nuclear
factor-kappa-light-chain-enhancer of activated B cells) plays an
indispensable role in the pathogenesis of acute or chronic
inflammation [12]. The NF-kB family consists of five members,
p65 (RelA), RelB, c-Rel, p50 and p52 that associate with each
other to form homo- or heterodimeric complexes. The NF-kB
molecules are retained in cytoplasm by interaction with inhibitor
of kappa-B (IkB). Upon stimulation, IkB will be degraded and
dissociated from NF-kB, which enables NF-kB migration from the
cytoplasm into the nucleus. Once activated by ligands, such as LPS
or TNFa, NF-kB will trigger the transcription of numerous genes
involved in pro-inflammatory responses [13–17]. Thus, targeting
or inhibiting NF-kB transactivation has potential therapeutic
value, as NF-kB is the key molecule involved in inflammatory
pathogenesis.
Though the versatility binding modes of thiosemicarbazone to
nickel ion have been reported, the biological effect of various N4-
substituted groups is unknown. In the present study, four
thiosemicarbazone derivatives of 2,3-dihydroxybenzaldehyde,
differing in the substituent on N4 of the thiosemicarbazone (H;
H3L
1, CH3; H3L
2, C6H5; H3L
3 and C2H5; H3L
4), were
synthesized and their anti-inflammatory effects were examined.
We presented evidence to show that one of the synthesized
compounds potently inhibited inflammation in vitro and in vivo.
Materials and Methods
Synthesis of thiosemicarbazone ligands and complexes
Triphenylphosphine was purchased from Merck, nickel(II)
[Ni(II)] chloride hexahydrate, potassium thiocyanate was from
Sigma-Aldrich and reagents were of analytical grade and used
without further purification. [NiCl2(PPh3)2] was prepared accord-
ing to the published procedure [18]. The thiosemicarbazone
ligands H3L(1–4) were prepared following the published proce-
dure [19] by reaction of 2,3-dihydroxybenzaldehyde with
thiosemicarbazide (H3L
1; ligand 1), 4-methyl-3-thiosemicarbazide
(H3L
2; ligand 2), 4-phenyl-3-thiosemicarbazide (H3L
3; ligand 3)
and 4-ethyl-3-thiosemicarbazide (H3L
4; ligand 4) in a 1: 1 molar
ratio, under standard reflux conditions. Complexes (5–8) were
synthesized according to the published works [20,21]. Complexes
[Ni(H2L
1)(PPh3)]Cl (5), [Ni(H2L
2)(PPh3)] (6), [Ni(HL
3)(PPh3)] (7)
and [Ni(HL4)(PPh3)] (8) were also named as complex 5, 6, 7 and 8
below. For biological testing, stock solutions (10 mg/ml) of these
compounds were prepared in 10% v/v aqueous dimethylsulfoxide
(DMSO) (Fisher chemicals).
IR and NMR spectra measurements
Infrared (IR) spectra were recorded as KBr pellets in the
frequency range of 400–4000 cm21 by using a Perkin-Elmer
Spectrum RX-1 spectrophotometer. Nuclear magnetic resonance
(NMR) spectra were recorded in deuterated DMSO-d6 on ECA
400 MHz instrument. Elemental analyses were performed on a
Pelkin-Elmer Analyst 400.
X-ray crystallography
Recrystallization of complex [Ni(HL3)(PPh3)] (7) from a mixture
of dimethylformamide/ethanol afforded plate purple crystals
whereas block red crystals of the complex [Ni(HL4)(PPh3)] (8)
were obtained from its methanol mother liquor. Data were
collected on a Bruker SMART APEX CCD area detector
diffractometer, equipped with a highly-oriented pyrolytic graphite
crystal incident beam monochromator and a molybdenum Ka
(l= 0.71073 A˚). The APEX2 software was used for data
acquisition and the SAINT software for cell refinement and data
reduction [22]. SADABS software was used for Absorption data
corrections [23]. The structures were solved and refined by
SHELXL97 package [24]. Molecular graphics were drawn by
using ORTEP [25].
Cell culture
RAW264.7, HeLa S3 and K562 cells were purchased from
ATCC. KCL22 cells was as previously described [26].
RAW264.7, K562 and KCL22 cells were cultured in RPMI,
while HeLa S3 and 293T-luc cells were cultured in DMEM. Both
media were supplemented with 10% fetal bovine serum, penicillin
G (100 mg/ml), and streptomycin (100 mg/ml). Cells were
maintained at 37uC with 5% CO2 in a humidified incubator.
Cell proliferation assay
A total number of 1.06104 cells per well were seeded into a 96-
well plate and incubated overnight at 37uC in 5% CO2. The next
day, the cells were treated with a two-fold serial dilution of
compounds. MTT assays were performed as described [27]. After
48 h, (4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazoliumbromide)
was added at 2 mg/ml. After 3 h of incubation at 37uC in 5%
CO2, DMSO was added to dissolve the formazan crystals. The
plates were then read in Chameleon multitechnology microplate
reader (Hidex, Turku, Finland) at 570 nm absorbance. The ratio
of the absorbance of treated cells to the absorbance of DMSO-
treated control cells was determined as percentage cell viability.
The concentration of compounds which resulted in a 50%
reduction in viability was defined as the IC50.
ORAC antioxidant assay
ORAC assay was performed based on reported procedures [28]
with slight modifications. Chemicals used such as fluorescein
sodium salt, AAPH (2,29-Azobis(2-methylpropionamidine) dihy-
drochloride), quercetin dehydrate and trolox ((6)-6-Hydroxy-
2,5,7,8-tetramethylchromane-2-carboxylic acid) were purchased
from Sigma-Aldrich. Compounds were diluted to a final concen-
tration of 100 mg/ml, with total reaction volume of 200 ml. The
assay was performed in a 96-well black microplate, with 25 ml of
samples, standard (trolox), blank (solvent/PBS) or positive control
(quercetin). Subsequently, 150 ml of working fluorescein solution
was added to each well. The plate was incubated at 37uC for at
least 5 min. Then, 25 ml of AAPH working solution was then
added to the wells to make a total volume of 200 ml. Fluorescence
was read in Chameleon multitechnology microplate reader
(Hidex, Turku, Finland) with excitation wavelength of 485 nm
and emission wavelength of 538 nm. Data were collected every
2 min for a duration of 2 h, and were analyzed by calculating the
differences of area under fluorescence decay curve (AUC) of
samples and blank. The values were expressed as Trolox
equivalent (TE).
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Figure. 1. Chemical structures of thiosemicarbazone complexes. (A) 2,3-dihydroxybenzaldehyde –N4-subsituted thiosemicarbazone, the
backbone structure of the complexes. (B) Chemical structures of thiosemicarbazone complexes with N4 substituted with –H, -CH3, - C6H5 and -C2H5
groups. These complexes were regarded as ligands. (C) Chemical structures of ligands with additional triphenyl phosphine group as coligand.
doi:10.1371/journal.pone.0100933.g001
Figure 2. Crystal structures of two of the complexes. (A) ORTEP diagram for complex [Ni(HL3)(PPh3)] (7). (B) ORTEP diagram for compound
[Ni(HL4)(PPh3)] (8).
doi:10.1371/journal.pone.0100933.g002
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Immunofluorescence staining
NF-kB Activation Kits (Thermo Scientific) were used as
previously described [29]. Cells were pretreated with compounds
for 4 h before being stimulated with lipopolysaccharide (LPS)
ortumour necrosis factor a (TNFa) for 1 h. Cells were then fixed
and permeabilized before probing with NF-kB p65 antibody for
1 h. Staining solution (containing DyLight 488 Goat Anti-Rabbit
and Hoechst dye) was then added and incubated for 1 h. The plate
with stained cells was evaluated using a Cellomics ArrayScan HCS
Reader (Cellomics, PA, USA). Data were captured, extracted and
analyzed with ArrayScan II Data Acquisition and Data Viewer
version 3.0 (Cellomics).
Immunoblot analysis
Cells were pretreated with or without of complex 5 (25 mg/ml
or 50 mg/ml) for 4 h before treatment with LPS (10 ng/ml) or
TNFa (10 ng/ml), for the indicated times. The cytoplasmic
extracts were prepared by using the hypotonic lysis buffer (10 mM
Tris, pH 7.5; 1.5 mM MgCl2; 10 mM KCl; 0.5 mM DTT;
0.5 mM PMSF; 16 Protease Inhibitor, 0.1% NP40) followed by
incubation on ice for 20 min and centrifugation at 3k rpm at 4uC
for 10 min. The supernatants were collected as cytoplasmic
extracts. The nuclear pellets were resuspended in the whole cell
lysis buffer (25 mM Tris, pH7.5; 420 mM NaCl; 1.5 mM MgCl2;
0.2 mM EDTA; 25% Glycerol; 0.5 mM DTT; 0.5 mM PMSF;
16 Protease Inhibitor). The nuclear extracts were then collected
by centrifugation at 15 krpm at 4uC for 10 min. Immunoblotting
was performed using antibodies against PARP (F-2, N-20),
HSP90a (C-20), p65 (C-20), IkBa (C-21) and p-IkBa from Santa
Cruz Biotech.
Quantitative PCR analysis
Cells pretreated with or without of complex 5 for 4 h were
incubated with LPS or TNFa for 4 h. Total RNAs were isolated
with Thermo Scientific GeneJET RNA Purification Kit. Compli-
mentary DNAs were synthesized and Quantitative PCR was
performed with 26 SYBR Green PCR Master mix (Thermo
Scientific) and run on the Bio-Rad CFX 96 Real-Time PCR
System. All data were then normalized to L32. The sequences of
the primers are listed in Supporting Information Table S1.
Luciferase reporter assay
293T cells were transduced with a lentivirus carrying luciferase
reporter driven by NF-kB enhancer found in immunoglobulin
kappa light chain gene to prepare 293T-luc cells. The 293T-luc
cells were pretreated with or without of complex 5 (12.5 mg/ml,
25 mg/ml, 50 mg/ml) for 4 h. The cells were later stimulated with
TNFa (10 ng/ml) for 12 h. Cells were scraped, collected into
1.5 ml tubes and centrifuged at 1.5 k rpm 4uC for 5 min before
removing the culture medium. Cell pellets were resuspended in
50 ml luciferase lysis buffer (100 mM Sodium Phosphate buffer,
pH7.8; 8 mM MgCl2; 1% Triton X-100; 15% glycerol; 1 mM
DTT). A total volume of 50 ml of luciferase substrate (containing
1 mM ATP; 0.25 mM luciferin; 1% BSA) was added to each well
on a white 96-well plate containing 20 mg lysate. Luciferase
activity was measured in 96-well plate with a VarioskanFlash
microplate reader (Thermo Scientific).
In vivo inflammatory assay
Male C57BL/6 mice at age 8–12 weeks old were from Jackson
Laboratories, USA. Mice were administrated intraperitoneally
(i.p.) with two different doses of complex 5 (2.5 mg/kg and 5 mg/
kg). Negative control groups were i.p. injected with 200 ml of
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vehicle (50% v/v ethanol). A standard drug 2 mg/kg dexameth-
asone (Sigma) was included in the study. After 1 h, paw edema was
induced by injecting 50 ml of 1% carrageenan (Sigma) through the
plantar tissue at the right hind paw of each mouse. The thickness
of right paw of each mouse was measured at 1, 3 and 5 h after
carrageenan was administered. Four animals per group were
tested (n = 4). Quantification of right hind paw thickness were
analyzed for statistical significance using Student’s t-test. Animals
were housed in individually ventilated cages in specific pathogen
free facility, Animal Experimental Unit, University of Malaya. All
efforts were made to minimize animal suffering and the number of
animals used. At the end of the experiment, mice were euthanized
by CO2 asphyxiation. Animal work was approved by the Faculty
of Medicine Animal Care and Use Committee (FOMIACUC) at
University of Malaya and reported according to ARRIVE
guidelines.
Molecular docking
GOLD (v 5.1; Genetic Optimization for Ligand Docking) [30]
was used to dock compounds into IkB kinase b (IKKb). The
bound inhibitor (compound 1) was used to indicate the binding site
(all protein atoms within 5.0 A˚) within the kinase domain of IKKb
(PDB 3RZF) [31]. The crystal structure of IKKb was treated by
Amber 12 with amber ff12SB force field and all hydrogen atoms
were added. GOLD was used to dock each ligand 10 times,
starting each time from a different random population of ligand
orientations and using the default automatic genetic algorithm
parameter settings. All torsion angles in each compound were
allowed to rotate freely. For the bound Ni atom, Zn was
substituted as the best surrogate for Ni [32].
Results
Spectroscopic characterization
Four complexes and four respective ligands were synthesized
and the chemical structures were as depicted (Figure 1). The most
Table 2. Selected bond lengths (A˚) and angles (u) for complex 8.
Bond lengths Bond angles
Ni1—O1 1.8510(12) O1—Ni1—N1 94.93(6)
Ni1—N1 1.8961(14) O1—Ni1—S1 173.72(4)
Ni1—P1 2.2059(5) N1—Ni1—S1 87.03(4)
Ni1—S1 2.1488(5) O1—Ni1—P1 88.61(4)
S1—C8 1.7529(18) N1—Ni1—P1 171.55(4)
P1—C17 1.8176(17) S1—Ni1—P1 90.261(18)
P1—C11 1.8264(18) C8—S1—Ni1 95.92(6)
P1—C23 1.8249(17) C7—N1—N2 112.62(14)
O1—C2 1.321(2) C7—N1—Ni1 125.76(12)
O2—C3 1.368(2) N3—C8—S1 118.33(13)
O2—H1 0.8400 N2—C8—S1 123.33(13)
N1—C7 1.297(2) N2— C8— N3 118.32(16)
N1—N2 1.400(2) C17— P1 —Ni1 114.97(6)
N2—C8 1.299(2) C11 —P1 —Ni1 114.64(6)
N3—C8 1.359(2) C23 —P1— Ni1 112.34(6)
doi:10.1371/journal.pone.0100933.t002
Table 3. Cell proliferation assay.
RAW264.7 HeLa S3
Complex IC50 (mg/ml) Complex IC50 (mg/ml)
H3L
1 (1) 22.8461.67 H3L
1 (1) .100
H3L
2 (2) 27.8460.96 H3L
2 (2) .100
H3L
3 (3) 31.4861.82 H3L
3 (3) .100
H3L
4 (4) 19.3761.07 H3L
4 (4) 87.1961.81
[Ni(H2L
1)(PPh3)]Cl (5) 28.6362.24 [Ni(H2L
1)(PPh3)]Cl (5) 29.3161.10
[Ni(H2L
2)(PPh3)]Cl (6) 37.7363.62 [Ni(H2L
2)(PPh3)]Cl (6) 77.5561.56
[Ni(HL3)(PPh3)] (7) 42.4464.17 [Ni(HL
3)(PPh3)] (7) .100
[Ni(HL4)(PPh3)] (8) 56.3163.86 [Ni(HL
4)(PPh3)] (8) .100
IC50 values of Ni(II) thiosemicarbazone ligands and their Ni(II)-phosphine complexes on RAW 264.7 cells and HeLa S3 cells at 48 h treatment.
doi:10.1371/journal.pone.0100933.t003
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significant IR bands for nickel(II) phosphine mixed complexes
of 2,3-dihydroxybenzaldehyde-N4-subsituted thiosemicarbazone
were collected with their tentative assignments (Table 1). The
crystal structures of complexes 5 and 6 have been described
previously [20,21]. The title complexes 7 and 8 crystallized into
orthorhombic crystal system. The molecular structures of
[Ni(HL3)(PPh3)] (7) and [Ni(HL
4)(PPh3)] (8) were as shown
(Figure 2A and 2B), while the selected bond lengths and bond
angles were as summarized (Table 2).
Cytotoxic effect of nickel complexes of
thiosemicarbazone
To examine whether synthesized Ni(II) thiosemicarbazone
ligands or Ni(II)-phosphine complexes were cytotoxic, we treated
RAW264.7 (leukemic monocyte macrophage) and HeLa S3
(cervical adenocarcinoma) cells with these compounds for 48 h.
The cell viability was determined with MTT assays [33]. These
compounds exerted low to moderate cytotoxicity on RAW264.7
cells with an IC50 ranging from 19.37 to 56.31 mg/ml (Table 3).
The proliferation of HeLa S3 cells was unaffected by most of the
compounds, with IC50 more than 100 mg/ml, suggesting better
tolerability to these compounds in HeLa S3 cells.
Complex 5 efficiently inhibits LPS-induced NF-kB
translocation
To investigate the anti-inflammatory effect, we treated
RAW264.7 cells with Ni(II) thiosemicarbazone ligands or Ni(II)-
phosphine complexes before stimulating them with LPS (a potent
inducer and activator of NF-kB). NF-kB acts as a central mediator
of inflammatory responses and compounds that inhibit NF-kB
activation are potential anti-inflammatory agents. To evaluate this,
we performed immunofluorescence staining of NF-kB p65. In the
absence of LPS, we showed that NF-kB p65 remained in the
cytoplasm of RAW264.7 cells (Figure 3). In response to LPS
stimulation, NF-kB p65 translocated from cytoplasm into the
nucleus, implying NF-kB activation (Figure 3). Next, we tested all
compounds using this model and found that complex 5 efficiently
inhibited LPS-mediated NF-kB p65 nuclear translocation at
25 mg/ml (Figure 3). Of note, the ligand of complex 5 (Ligand
1, H3L
1) and other compounds did not affect NF-kB translocation
at similar concentration. Moreover, we observed that complex 6–8
required higher concentration (.50 mg/ml) to elicit similar
inhibitory effect (data not shown).
Complex 5 inhibits NF-kB translocation by interrupting
IkB degradation
Next, complex 5 was chosen for subsequent mechanistic study
due to its potent inhibitory effect on NF-kB p65 nuclear
translocation. In the absence of stimulant, IkBa forms a complex
with NF-kB p65 in the cytoplasm. Upon activation by LPS, the
degradation of IkBa enables nuclear translocation of p65. To
examine the status of IkB in the presence of complex 5, we
pretreated RAW264.7 cells with complex 5 or DMSO for 4 h
before incubating with LPS for various time periods. Cytoplasmic
Figure 3. Effect of N4-substituteted thiosemicarbazone complexes on LPS-induced NF-kB nuclear transloction in RAW264.7
macrophage cells. Staining of Hoechst (nucleus) and NF-kB in RAW264.7 cells. Cells were pre-treated with 25 mg/ml of compounds for 4 h,
followed by LPS stimulation for 1 h.
doi:10.1371/journal.pone.0100933.g003
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and nuclear extracts were separated and analyzed with immuno-
blotting using anti-IkBa and anti-p65 antibodies (Figure 4A and
4B). After 15 min of LPS stimulation, we observed degradation of
IkBa in the cytoplasm. This occurred in conjunction with the
translocation of p65 into the nucleus in control cells. Pre-treating
the cells with complex 5 inhibited both IkBa degradation and p65
nuclear translocation in response to LPS stimulation. The
separation of cytoplasmic and nuclear extracts was verified with
immunoblotting using antibodies against PARP (a nuclear protein)
and HSP90 (a cytoplasmic protein). Taken together, these results
suggest that complex 5 attenuates LPS-induced activation of NF-
kB by inhibiting IkBa degradation.
Complex 5 inhibits TNFa-induced NF-kB translocation in
HeLa S3 cells
To examine whether complex 5 blocks the activation of NF-kB
by another agonist, similar experiments were performed on HeLa
S3 cells induced with TNFa. Similar to LPS-treated RAW264.7
cells, TNFa-induced translocation of NF-kB p65 in HeLa S3 cells
(Figure 5A). Pretreatment of HeLa S3 cells with a very low
concentration of complex 5 (6.25 mg/ml) significantly blocked
TNF-induced translocation of NF-kB. Moreover, biochemical
fractionation showed that pre-treating HeLa S3 cells with complex
5 dramatically reduced IkBa degradation and p65 translocation in
response to TNFa stimulation (Figure 5B and 5C). In addition, we
found that TNF-induced phosphorylation of IkBa was inhibited
Figure 4. Complex 5 blocks LPS-induced NF-kB nuclear translocation by inhibiting IkBa degradation. (A) RAW264.7 cells pretreated with
or without complex 5 for 4 h were treated with LPS for the indicated time points. Cytoplasmic and nuclear extracts were prepared and were
subjected to Western blot analysis with IkBa, p65, HSP90 and PARP antibodies. (B) Relative density of IkBa and p65. Western blot signal intensities
were quantified using ImageJ software. Densities were normalized to 0 min DMSO.
doi:10.1371/journal.pone.0100933.g004
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by complex 5 (Figure 5D). TNF stimulation induced a rapid
phosphorylation of IkBa in DMSO treated cells (within 5
minutes). Pretreating cells with complex 5 completely abolished
TNF-mediated phosphorylation of IkBa, thus protecting IkBa
from TNF-induced degradation.
Complex 5 blocks NF-kB transactivation activity
To test if complex 5 inhibits NF-kB-mediated gene expression,
we cultured RAW264.7 cells with or without complex 5 for 4 h
before treating the cells with LPS for 4 h. Cells were collected for
RNA isolation and real time PCR analysis (Figure 6A). Our results
showed that LPS-induced expression of NF-kB target genes,
TNFa, IFNb, IL6 and IP10 was abolished following pretreatment
of the cells with complex 5.
In addition, we investigated the effect of complex 5 on NF-kB-
mediated gene expression in response to TNFa stimulation in
human HeLa S3 cells. We treated HeLa S3 cells with complex 5
for 4 h before TNFa treatment for 4 h. A marked decrease in the
expression of NF-kB target genes, including IL8, TNFa, IL6,
ICAM1, CCL5 and A20, was observed in complex 5-treated cells
compared to control (Figure 6B). Similar results were obtained in
two CML cell lines, K562 and KCL22 (Figure 6C). Furthermore,
we showed that complex 5 inhibited TNF-induced expression of
COX-2 in a dose dependent manner (Supporting Information
Figure S1). Taken together, these results suggest that complex 5
attenuates both LPS- and TNFa-induced transcription of NF-kB
regulated genes associated with inflammatory response.
To examine whether complex 5 could inhibit NF-kB transacti-
vation activity, we performed luciferase reporter assay using 293T-
luc cell line stably transduced with a promoter containing NF-kB
elements-driven luciferase reporter gene (Figure 6D). The cells
were pretreated with complex 5 for 4 h, followed by TNFa for
12 h before measuring the luciferase activities. Our data showed
that the luciferase activity was induced 8-fold by TNFa stimulation
in control cells. Whereas treating the cells with complex 5
significantly reduced the luciferase activity in a dose-dependent
manner (Figure 6D), indicating that complex 5 efficiently inhibits
NF-kB transactivation activity.
Complex 5 suppresses acute inflammation in vivo
Next, we examined the anti-inflammatory effects of complex 5
in a carrageenan-induced paw edema mouse model. We first
Figure 5. Complex 5 blocks TNFa-induced NF-kB nuclear translocation. Complex 5 inhibits TNFa -induced NF-B nuclear translocation. (A)
NF-kB activation assay on TNFa treated HeLa S3 cells. Staining of Hoechst (nucleus) and NF-kB in HeLa S3 cells. Cells were pre-treated with 25 mg/ml
of Ligand 1 and Complex 5 for 4 h, followed by TNFa stimulation for 1 h. (B) HeLa S3 cells pretreated with or without complex 5 for 4 h were
incubated with TNFa for the indicated time points. Cytoplasmic and nuclear extracts were prepared and were subjected to western blot analysis with
IkBa, p65, HSP90 and PARP antibodies. (C) Relative density of IkBa and p65. Western blot signal intensities were quantified using ImageJ software.
Densities were normalized to 0 min DMSO. (D) HeLa S3 cells pretreated with or without complex 5 for 4 h were incubated with TNFa for the
indicated time points. Whole cell extracts were prepared and were subjected to western blot analysis with IkBa, p-IkBa and PARP antibodies.
doi:10.1371/journal.pone.0100933.g005
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tested the acute toxicity effect of complex 5 in C57BL/6 mice. All
tested mice displayed no overt abnormalities during a 14 day
observation period. Renal and liver functional tests suggested that
a low amount of complex 5 up to 125 mg/kg or 250 mg/kg was
safe for consumption, but a higher concentration at 500 mg/kg
may be cytotoxic to the host (Supporting Information Table S2
and S3).
To test the in vivo inhibitory effect of complex 5 on
inflammation, we administrated two doses of complex 5
(2.5 mg/kg and 5.0 mg/kg) into C57BL/6 wild type mice through
i.p. injection. For a positive control, we performed i.p. injection of
2.0 mg/kg dexamethasone into the mice. After 1 h, paw edema in
the mice was induced by injecting 1% carrageenan to the right
hind paw. The paw sizes were measured at 1, 3 and 5 h after
edema induction. The edema formation at the mice paw was due
to inflammatory response causing the accumulation of histamine,
serotonin, prostaglandin and other secreted inflammatory medi-
ators. From visual observation, the group of mice administrated
with 5.0 mg/kg complex 5 demonstrated obvious reduction of
paw edema formation (Figure 7A). One hour after induction of
inflammation, paw size in control mice increased to 7.360.8 mm.
In mice preinjected with 2.5 mg/kg or 5.0 mg/kg of complex 5,
we observed a reduction of paw size to 5.860.4 mm and
5.060.2 mm, respectively. This was comparable to the paw size
(4.660.4 mm) in mice pretreated with standard drug, dexameth-
asone (Figure 7B). At 3 and 5 h post carrageenan administration,
paw edema was further reduced in complex 5-treated mice
compared to untreated mice, supporting the ability of complex 5
to suppress acute inflammation in vivo.
Complex 5 does not function as an anti-oxidant
The association between inflammation and reactive oxygen
species (ROS) has been demonstrated by a previous study [34].
ROS may amplify inflammatory responses via up-regulation or
activation of certain genes/transcription factors, such as NF-kB.
Several reports have suggested the possible antioxidant capacity of
some transition metals such as copper and iron [35,36]. Therefore,
we conducted ORAC assays to investigate the antioxidant capacity
of complex 5. The ORAC assay uses peroxyl radical as pro-
oxidant and the antioxidant activity is quantified via area under
curve (AUC) [37]. We included quercetin, a known antioxidant, as
a positive control. We found that complex 5, as well as the other
nickel-containing complexes synthesized exhibited low antioxidant
activity compared to quercetin (Table 4), indicating that these
Figure 6. Complex 5 inhibits NF-kB transactivation activity. (A) RAW264.7 cells pretreated with or without complex 5 for 4 h were treated
with LPS for 4 h. The expression of TNFa, IFNb, IL6 and IP10 were measured by QPCR. (B) HeLa S3 cells pretreated with or without complex 5 for 4 h
were stimulated with TNFa for 4 h. The expression of TNFa, IL8, CCL5, ICAM1, IL6 and A20 were measured by QPCR. (C) K562 or KCL22 cells pretreated
with or without 50 mg/ml of complex 5 for 4 h were stimulated with 100 ng/ml TNFa for 2 h. The expression of IL8 and TNF were measured by QPCR.
(D) 293T-luc reporter cells pretreated with or without various concentrations of complex 5 were stimulated with TNFa for 12 h. Cell lysates were
prepared and the luciferase activities were measured. Error bars represent the variation range of duplicate experiments. Asterisks represents statistical
significance by Student’s t-test (*P,0.05).
doi:10.1371/journal.pone.0100933.g006
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compounds have little or no antioxidant activity. Therefore, we
suggest that complex 5 does not function as an antioxidant as it is
not a potent ROS scavenger.
Complex 5 docks to active site of IKKb
To further understand the mechanism of complex 5 mediated
inhibition of NF-kB activation, we reasoned that degradation of
IkB to activate NF-kB can be achieved by the upstream activation
of IKK kinases [14]. To give some further clues as to whether
complex 5 might inhibit IKK kinases, complex 5 was docked to
IKKb, for which the crystal structure is available [31]. Complex 5
was successfully docked into the kinase domain of IKKb and the
triphenylphosphine docked deep into the active site (Figure 8A).
The alignment of complex 5 and a previously known inhibitor
[31], showed a good overlay and potentially mimics the molecular
interactions of the inhibitor (Figure 8B). Based on this docking
pose (Figure 8C), we can speculate that the triphenylphosphine is
‘‘locked’’ deeply into the binding site and have hydrophobic
interactions with surrounding residues. The hydrophilic side chain
of complex 5 points outside the binding site and forms one
hydrogen bond with TYR98. This docking pose gives a possible
explanation as to why those compounds without triphenylpho-
sphine have poor biological activities. Further, complexes 6 to 8
contain larger hydrophobic side chains that would point towards
the solvent accessible area, which may preclude binding in a
similar pose.
Discussion
In the present study, we synthesized four thiosemicarbazones
derivatives of 2,3-dihydroxybenzaldehyde, differing in the substit-
uent on N4 of the thiosemicarbazone (H; H3L
1, CH3; H3L
2,
C6H5; H3L
3 and C2H5; H3L
4). We have described the synthesis,
characterization and anti-inflammatory activities of Ni(II) thio-
semicarbazone complexes with incorporated triphenylphosphine
as an auxiliary ligand. Results from spectroscopic data and crystal
Figure 7. Complex 5 suppresses acute inflammatory responses in vivo. Male C57BL/6 mice at age of 8-12 weeks old were non-injected or
injected i.p. with 2.5 mg/kg or 5.0 mg/kg complex 5, whereas for positive controls, mice were injected i.p. with 2.0 mg/kg dexamethasone. After 1 h,
acute inflammation was induced in the right hind paw of each mice by injecting 50 ml of carrageenan. The size of the paw were measured after (A)
1 h or, (B) 1, 3 and 5 h post carrageenan injection. Shown were mean6SD (n = 4). Statistical analysis was performed with Student’s t-test. At 1 h post-
carrageenan induction, control versus 2.5 mg/kg complex 5 (P,0.05), control versus 5.0 mg/kg complex 5 (P,0.01), and control versus 2.0 mg/kg
dexamethasone (P,0.01).
doi:10.1371/journal.pone.0100933.g007
Table 4. ORAC assay.
Complex mM TE per 100 mM
H3L
1 (1) 5.1860.05
H3L
2 (2) 8.2360.43
H3L
3 (3) 9.7160.77
H3L
4 (4) 7.5461.61
[Ni(H2L
1)(PPh3)]Cl (5) 10.5660.17
[Ni(H2L
2)(PPh3)]Cl (6) 15.6560.89
[Ni(HL3)(PPh3)] (7) 9.3761.14
[Ni(HL4)(PPh3)] (8) 13.3461.49
Quercetin 24.4160.35
Antioxidant capacity of Ni(II) thiosemicarbazone ligands and their Ni(II)-
phosphine complexes by ORAC assay.
doi:10.1371/journal.pone.0100933.t004
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structure analysis showed that these four complexes are coordi-
nated with the ONS tridentate thiosemicarbazone ligand bounded
to Ni(II) through phenolic oxygen, azomethine nitrogen and
thiolate/thione sulfur. Of note, we found that the N4-substituted
groups on the thiosemicarbazone moiety may influence both the
coordination mode of thiosemicarbazone to Ni(II) and their
inhibitory effect on NF-kB translocation.
The biological activities of the Ni(II) complexes are possibly
influenced by the type of N4 substituents as well as the presence of
co-ligands. Our findings suggested that ligands 1 to 4 demon-
strated very little effect on the blockage of LPS-mediated nuclear
translocation of NF-kB in RAW264.7 cells compared to
complexes 5 to 8, indicating the importance of co-ligands in
mounting the inhibitory activity. Among the synthesized com-
plexes 5, 6, 7 and 8, interestingly, only complex 5 showed a
marked inhibition of NF-kB translocation. The inhibitory activity
of complex 5 could be related to the square planar geometry,
which is coordinately unsaturated. Further details on the
compounds were as provided (Supporting Information Discussion
S1). Based on the findings, we observed that the inhibition
efficiency of Ni(II) complexes with 2,3-dihydroxybenzaldehyde
N4- thiosemicarbazone in the presence of auxiliary ligand can be
arranged according to the substituents on N4 of the thiosemicar-
bazone moiety as phenyl , C2H5 , CH3 ,H. The higher
inhibition efficiency by complex 5 may be attributed to the less
steric hindrance between the unsubstituted N4- thiosemicarbazone
with its potential interactive target such as IKKb as demonstrated
in this study.
MTT cell viability assays showed that compounds 1–8 were
relatively less cytotoxic to RAW264.7 and HeLa S3 cells (IC50.
15 mg/ml), as compared to the US National Cancer Institute
recommended guideline for pure compound (IC50,4 mg/ml) [38].
In fact, as low as 6.25 mg/ml of complex 5 is sufficient to prevent
TNFa-induced NF-kB nuclear translocation after 4 h treatment in
HeLa S3 (cell viability still remained .90%), indicating that the
inhibition effect was not due to cell death or apoptosis.
Importantly, complex 5 did not showed significant cell growth
inhibition on primary Human Umbilical Vein Endothelial Cells
(HUVEC), with IC50.80 mg/ml, indicating less cytotoxicity
towards normal cells. Further acute toxicity test in C57BL/6
mice showed that complex 5 could be well tolerated up to
250 mg/kg. Of note, we observed that 5 mg/kg of complex 5
effectively reduced carrageenan-induced paw edema formation,
supporting the notion that complex 5 is a potential anti-
inflammatory agent, consistent with the in vitro experiments using
cell lines.
In response to inflammatory stimulants, such as LPS and TNFa,
cells could mount immune responses through the activation of NF-
kB, a key transcription factor that regulates innate and adaptive
immune responses. NF-kB is a transcription factor whose activity
is regulated mainly by its nuclear translocation. In resting cells,
NF-kB is sequestered in the cytoplasm through its association with
IkBa. In response to stimuli, such as proinflammatory cytokines
and pathogen-associated molecules, IkBa is phosphorylated by
IKKb and degraded by ubiquitin-proteasome. Degradation of
IkBa released NF-kB and enabled its translocation into the
nucleus to activate multiple inflammatory-associated genes [14].
Among the NF-kB target genes examined, TNFa, IFNb, IL6 and
IL1b are pro-inflammatory cytokines that exacerbates inflamma-
tory responses. CCL5 (Rantes), IL8 (CXCL8), and IP10
(CXCL10) functions as chemoattractant for other immune cells
while ICAM is ligand for LFA-1 integrin that promotes leukocyte
adhesion to endothelial cells and transmigration into tissue. A20
(TNFAIP3) is a ubiquitination-associated protein which plays an
important role in the NF-kB pathway activation. Our study
showed that complex 5 treatment could block NF-kB nuclear
Figure 8. Molecular docking of complex 5 to IKK complex. (A) The binding of complex 5 in the kinase domain of IKKb. The protein is
represented by the protein surface and complex 5 in a stick model. (B) The overlay of complex 5 and inhibitor (compound 1 [30]). The inhibitor is
represented by a balls and sticks model and complex 5 by a sticks model, in which the Nickel is colored in orange, nitrogen is colored in blue, oxygen
is in red, carbon is in grey, sulphur is in green, hydrogen in white and phosphate is in purple. (C) The interaction between complex 5 and the binding
site. One hydrogen bond is formed between complex 5 and TYR98, which is indicated by a green dotted line.
doi:10.1371/journal.pone.0100933.g008
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translocation and attenuate the expression of these proinflamma-
tory genes after TNFa or LPS stimulation, further supporting its
potential role as an anti-inflammatory agent.
To understand the underlying inhibitory mechanism, we
performed cytoplasmic/nuclear fractionation and Western blot-
ting. Results showed that both TNFa- and LPS-induced IkBa
protein degradation was blocked in the presence of complex 5,
suggesting that complex 5 impaired the upstream signaling
pathway that involves the IKK kinase complex. Activated IKK
complex phosphorylates and promotes the degradation of IkB,
thus enables nuclear translocation of NF-kB. Using molecular
docking, we demonstrated potential interactions between complex
5 and the active site of IKKb in a manner that mimics the
interactions with a known inhibitor [31]. In this position, the
triphenylphosphine appears to bind deep with the hydrophilic side
chain of complex 5 pointing outside the binding site, forming one
hydrogen bond with TYR98, which gives a possible explanation as
to why those compounds without triphenylphosphine or that
contain larger hydrophobic side chains have poor biological
activities. Thus, we propose that interaction of IKKb with
complex 5 could reduce LPS- or TNFa-mediated IkBa degrada-
tion, which subsequently blocked NF-kB nuclear translocation.
In conclusion, we found that complex 5 efficiently blocked
TNF- or LPS-induced NF-kB nuclear translocation compared to
other tested compounds. This resulted in lower transcriptional
activity, as reflected by the downregulation of pro-inflammatory
cytokines mRNA levels. Further in vivo studies showed that
complex 5 could suppress acute inflammation in mice. As a pilot
study, molecular docking was used to predict complex 5 binding at
the active site of IKKb, which could explain how complex 5 might
interrupt the LPS or TNFa-induced IKK/IkBa/NF-kB activation
pathway.
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